We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+10.32%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$871M
AUM Growth
+$146M
Cap. Flow
+$118M
Cap. Flow %
13.5%
Top 10 Hldgs %
47.29%
Holding
141
New
32
Increased
44
Reduced
18
Closed
28

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$43.2M
2
BMY icon
Bristol-Myers Squibb
BMY
+$32M
3
VTRS icon
Viatris
VTRS
+$17.7M
4
ARGX icon
argenx
ARGX
+$12.1M
5
IMMU
Immunomedics Inc
IMMU
+$9.29M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$21.4M
2
AMGN icon
Amgen
AMGN
+$18.5M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$15.6M
4
BIIB icon
Biogen
BIIB
+$14.5M
5
PFE icon
Pfizer
PFE
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 75.17%
2 Technology 4.8%
3 Industrials 2.36%
4 Financials 1.58%
5 Materials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNA
76
DELISTED
Allena Pharmaceuticals
ALNA
$3.17M 0.36%
295,199
+27,850
+10% +$306K
TBIO
77
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$2.77M 0.32%
276,639
+146,639
+113% +$1.71M
CRVS icon
78
Corvus Pharmaceuticals
CRVS
$1.12B
$2.76M 0.32%
321,430
-14,557
-4% -$146K
CYPH
79
Cypherpunk Technologies Inc
CYPH
$62.9M
$2.59M 0.3%
33,253
-16,661
-33% -$1.24M
DOVA
80
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$2.52M 0.29%
+120,000
New +$2.86M
VTGN icon
81
VistaGen Therapeutics
VTGN
$9.89M
$2.43M 0.28%
55,797
+10,067
+22% +$408K
SVRA icon
82
Savara
SVRA
$1.12B
$2.34M 0.27%
+209,596
New +$2.41M
ALLT icon
83
Allot
ALLT
$372M
$2.33M 0.27%
+376,451
New +$2.21M
MTEM
84
DELISTED
Molecular Templates, Inc.
MTEM
$2.16M 0.25%
+26,667
New +$2.04M
FLEX icon
85
Flex
FLEX
$41.7B
$2.09M 0.24%
211,722
-133,064
-39% -$1.39M
UROV
86
DELISTED
Urovant Sciences Ltd.
UROV
$1.97M 0.23%
+164,030
New +$1.94M
VRCA icon
87
Verrica Pharmaceuticals
VRCA
$89.7M
$1.9M 0.22%
11,700
-880
-7% -$150K
SRRA
88
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.74M 0.2%
25,569
-1,326
-5% -$120K
AQST icon
89
Aquestive Therapeutics
AQST
$464M
$1.67M 0.19%
+95,300
New +$1.57M
GILT icon
90
Gilat Satellite Networks
GILT
$834M
$1.4M 0.16%
163,367
– –
CARM
91
DELISTED
Carisma Therapeutics
CARM
$1.35M 0.16%
31,500
-87,353
-73% -$3.4M
ZYME icon
92
Zymeworks
ZYME
$1.61B
$1.16M 0.13%
73,800
– –
PHXM
93
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$1.05M 0.12%
+12,000
New +$1.25M
AAP icon
94
Advance Auto Parts
AAP
$3.35B
$898K 0.1%
5,336
– –
AUDC icon
95
AudioCodes
AUDC
$244M
$596K 0.07%
59,226
– –
UNH icon
96
UnitedHealth
UNH
$376B
$532K 0.06%
2,000
– –
RDWR icon
97
Radware
RDWR
$1.1B
$464K 0.05%
17,527
– –
CHTR icon
98
Charter Communications
CHTR
$17.3B
$462K 0.05%
1,419
– –
ADVM
99
DELISTED
Adverum Biotechnologies
ADVM
$454K 0.05%
+7,500
New +$421K
VKTX icon
100
CALL
Viking Therapeutics
VKTX
$3.7B
$416K 0.05%
+23,900
New +$284K
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2018 Portfolio in Review

As of Q3 2018, Sphera Funds Management held 141 positions worth $871M, up 20% from $725M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sphera Funds Management deployed $118M of net new capital in Q3 2018, opening 32 new positions and adding to 44 existing holdings. Its largest new stake was Johnson & Johnson: 325,000 shares worth $44.9M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 72% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $15.6M trimmed.

  • Sphera Funds Management's largest Q3 2018 buy was Johnson & Johnson: 325,000 shares worth $44.9M.
  • Sphera Funds Management added most to Viatris in Q3 2018, an estimated $17.7M increase.
  • Sphera Funds Management's biggest Q3 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $15.6M.
  • Sphera Funds Management fully exited Shire pic in Q3 2018, selling an estimated $21.4M.
  • Sphera Funds Management's ten largest holdings make up 47% of its $871M portfolio in Q3 2018.
  • Sphera Funds Management opened 32 new positions and closed 28 in Q3 2018.
  • Sphera Funds Management's portfolio value rose 20% quarter-over-quarter to $871M.

Based on Sphera Funds Management's 13F filing for Q3 2018, filed 14 Nov 2018.